Novartis hails single-dose H1N1 success

Racing to produce a huge quantity of vaccine to guard against an expected tsunami of swine flu cases this fall, Novartis says that a single low dose of its Celtura jab produced an immune response sufficient to protect the volunteers enrolled in a small trial. The cell culture-based vaccine was tested in a small trial involving 100 people, says the giant pharma manufacturer. Researchers are now studying Celtura in trials involving 6,000 people. FierceVaccines